AN2 Therapeutics, Inc. (ANTX)
| Previous Close | 2.2800 |
| Open | 2.3000 |
| Bid | 2.3200 x 100 |
| Ask | 2.3400 x 100 |
| Day's Range | 2.2000 - 2.3700 |
| 52 Week Range | 2.2000 - 22.2200 |
| Volume | |
| Avg. Volume | 481,490 |
| Market Cap | 69.514M |
| Beta (5Y Monthly) | -0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
13 Best Falling Stocks To Buy Right Now
In this piece, we will take a look at the 13 best falling stocks to buy now. If you want to skip our coverage of the latest stock market news, then you can take a look at the 5 Best Falling Stocks To Buy Right Now. The start of the year has seen some stocks […]
- Reuters
UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment
AN2 Therapeutics said on Monday it will pause further enrollment in a mid-to-late-stage study testing its experimental drug to treat a type of bacterial lung infection, citing potentially lower-than-expected efficacy. The company was conducting a mid-stage study testing epetraborole, a once-daily oral drug to treat MAC lung disease, caused by bacterial infection. AN2 said the decision to pause enrollment will give time to further evaluate the study data and it expects to announce top-line results from the study in the summer.
- Simply Wall St.
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
